By Vincent Cruz

J-beauty has earned its American following: meticulous formulations, elegant sunscreens, and a reputation for gentle, effective skincare. But Japan’s cosmetics regulatory system is one of the most distinctive in the world, and almost none of it maps onto America’s MoCRA framework. The category that defines many Japanese best-sellers — the quasi-drug — does not even exist in U.S. law.

This guide is for the Japanese brand owner planning a U.S. launch. For the full compliance picture, start with the MoCRA Compliance Guide for Cosmetic Brands.

The core rule: Japanese compliance does not transfer

Everything in this guide follows from one fact: FDA does not recognize Japanese compliance as a substitute for U.S. compliance. Specifically:

Your cosmetics marketing and manufacturing licenses (issued through the prefectures) have no standing with FDA. They prove you can sell legally in Japan, nothing more.
Your quasi-drug approvals mean nothing to FDA — and are often a warning sign that the product will be regulated as a drug in the U.S.
Your Japanese safety data, quality records, and GMP compliance are evidence of good practice, but none of them satisfies a U.S. filing requirement.
Your full-ingredient Japanese labeling does not satisfy U.S. labeling law, which has its own names, order, and format.

Plan your U.S. launch as a fresh compliance project, not an extension of your Japanese paperwork.

Step 1: Register your facility with FDA

If your products are manufactured or processed in Japan (or anywhere outside the U.S.) for sale in America, the facility must register with FDA. Key points for Japanese brands:

You need an FEI number first. The FDA Establishment Identifier is required before registration can be filed. Request it from FDA by email; processing typically takes 7 to 10 business days. Run the free FEI check to see whether your facility already has one.
Registration is filed through Cosmetics Direct, FDA’s online portal, using Form FDA 5066. The step-by-step process is covered in Cosmetics Direct: How to Register Your Facility.
Registration renews every two years, based on your facility’s initial registration date, with automated reminders from FDA. See MoCRA Biennial Renewal Explained.
Using a Japanese OEM or contract manufacturer? Japan’s industry runs on contract manufacturing, but the rule is simple: the facility that makes the product is the one that registers. If an OEM lab makes your products, that lab’s facility registers (and needs its own U.S. agent). See Private Label Cosmetics: Who Registers Under MoCRA.

A common mistake: assuming your American importer’s paperwork covers your factory. It does not. The manufacturing facility registers; a distributor cannot register on the manufacturer’s behalf.

Step 2: Name a U.S. agent

Every foreign facility registering with FDA must designate a U.S. agent: a person or business physically present in the United States who serves as FDA’s official contact for the facility. This is not optional, and neither your Tokyo headquarters nor a Japanese trading company can fill the role unless it maintains a real U.S. presence.

The agent receives FDA correspondence, relays it to you, and is the contact FDA reaches out to with questions about your facility. Our own service is a flat $450 one-time setup plus $34.99 per month per facility. For how to evaluate providers, see How to Choose a MoCRA U.S. Agent and Who Can Be a MoCRA U.S. Agent.

Step 3: List your products

Each cosmetic product sold in the U.S. must be listed with FDA through Cosmetics Direct (Form FDA 5067), filed by the responsible person — the manufacturer, packer, or distributor whose name appears on the label. Listings include product and ingredient information and must be updated annually.

Your domestic product notifications to the prefecture have no U.S. effect; the U.S. listing is a separate filing in a different system. Do both. For how registration and listing differ, see Facility Registration vs Product Listing Explained.

Step 4: Fix your labels for the U.S. market

Japanese labels do not comply with U.S. labeling law, even in translation. The differences that matter most:

Full English translation. All required label information must be in English. A partial English sticker on a Japanese label rarely covers everything U.S. law requires.

Ingredient names and order. Japan uses Japanese-language ingredient display names. The U.S. requires English INCI names in descending order of predominance. Some Japanese display names do not map one-to-one onto U.S. INCI names, so the list needs a proper conversion, not just a translation.

Color additives — check every single one. Every color additive in a product sold in the U.S. must be one FDA permits for that use, and some colors require FDA batch certification — the actual batch must be certified before use. A color legal in Japan may be banned in the U.S., restricted to certain product types (for example, not permitted around the eyes), or legal only in certified batches. Check every color in lip, eye, and makeup products before you ship.

Net quantity. U.S. consumer commodities must state net quantity in both U.S. customary and metric units, in a specific location on the principal display panel. Metric-only Japanese labels need updating.

Domestic contact for adverse events. MoCRA requires every label to carry domestic contact information — a U.S. address, U.S. phone number, or electronic contact — through which consumers can report adverse events. A Japanese address and phone number do not serve this purpose.

Claims review. Claims that are routine in Japan can be drug claims in the U.S. “Medicated,” whitening claims about suppressing melanin, and hair-growth claims all need re-evaluation before the product ships. See Is Your Product a Cosmetic or a Drug? and MoCRA Labeling Changes.

The pitfalls that catch Japanese brands specifically

The quasi-drug trap. Japan’s quasi-drug category (medicated whitening essences, hair-growth tonics, anti-acne products, medicated soaps) sits between cosmetics and drugs. U.S. law has no such category: the claims and active ingredients that make a product a quasi-drug in Japan usually make it a drug in the U.S. Products that claim to suppress melanin, grow hair, or treat acne are drug products in America, with an entirely different FDA pathway. Many flagship J-beauty products need reclassification, reformulation, or new claims to be sold as cosmetics.
Sunscreens. Japanese sunscreens are world-famous, and the PA++++ rating system is a point of pride. In the U.S., sunscreen is a drug, not a cosmetic: SPF and PA claims cannot appear on a cosmetic label, and selling sunscreen means the drug pathway — different registration, Drug Facts labeling, drug standards.
Color additives. Assuming your Japanese color palette is U.S.-legal. It may not be, and uncertified batches of certifiable colors are a shipment-level problem.
Relying on the importer. Your U.S. importer or distributor may offer to “handle compliance.” They cannot register your Japanese facility or serve as its U.S. agent unless they formally take on that role and meet FDA’s requirements.
Small-business exemption confusion. The U.S. small-business exemption (Section 612 of the FD&C Act, 21 U.S.C. section 364h) is based on U.S. sales, not Japanese revenue, and never exempts labeling, safety substantiation, or adverse event reporting. Check the exemption worksheet rather than assuming.
Forgetting the ongoing duties. Registration is not a one-time event: biennial renewal, annual listing updates, serious adverse event reporting to FDA within 15 business days, and adverse event records kept for six years. See MoCRA Adverse Event Reporting.

How J-beauty brands compare with K-beauty on this

The filing mechanics are the same ones Korean brands face — facility registration, U.S. agent, product listings — covered in our MoCRA guide for Korean brands. The Japanese-specific risks are the quasi-drug backlist and color additives. Audit those first.

A realistic Japan-to-US launch sequence

Classify every product as cosmetic or drug for the U.S. market — starting with every quasi-drug in your line.
Confirm whether you qualify for the small-business exemption; if not, proceed with full compliance.
Request your facility’s FEI number (7 to 10 business days).
Choose and appoint your U.S. agent.
File facility registration via Cosmetics Direct.
File product listings.
Finalize U.S.-compliant labels: full English conversion, dual net quantity, domestic contact, and a color-additive check on every shade.
Set up adverse event intake and record-keeping from day one.

For realistic timing on each step, see How Long Does MoCRA Facility Registration Take?.

FAQ

My product is a quasi-drug in Japan. What is it in the U.S.? Probably a drug. The U.S. has no quasi-drug category. Products that claim to whiten skin by affecting melanin, grow hair, or treat acne meet the U.S. definition of a drug, regardless of Japanese status; products with milder, appearance-only claims may qualify as cosmetics. Every quasi-drug needs an individual classification review.

Does my Japanese cosmetics license count for anything with FDA? No. Your licenses authorize you to sell in Japan. FDA requires its own facility registration, product listings, and U.S. agent designation, and credits none of your Japanese approvals toward them.

Can my U.S. importer or distributor be my U.S. agent? Only if they formally agree to serve as the agent and meet FDA’s requirements — a person or business physically present in the United States. An ordinary distribution arrangement does not make them your agent, and the designation must be part of your facility registration.

Do the colors in my products need FDA approval? Every color additive must be one FDA permits for that specific use, and some must come from FDA-certified batches. A color legal in Japan can be prohibited in the U.S. or restricted (for example, not for use around the eyes). Verify each color before producing for the U.S. market, not after.

Can I just translate my Japanese label? Translation is necessary but not sufficient. U.S. labels also need U.S. INCI names in the U.S. order and format, dual-unit net quantity, a domestic contact for adverse event reports, and claims that survive U.S. cosmetic-versus-drug rules.

How long does the whole process take for a Japanese brand? The FEI request alone takes 7 to 10 business days; classification reviews, agent appointment, and label redesign add more. Plan for several weeks minimum from a standing start; see How Long Does MoCRA Facility Registration Take?.

Next step: Japanese brand planning a U.S. launch? Contact us for a straight assessment of what your products need, or run the free FEI check to confirm whether your facility already has an FDA Establishment Identifier.

This article is for educational purposes only and is not legal advice. US MoCRA Agent is a private service provider and is not affiliated with or endorsed by the FDA.